Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design

References

• Lang AE, Lozano AM. (1998). Parkinson’s disease. First of two parts. N Engl J Med, 339:1044–1053.
   PubMed Web of Science ®Google Scholar
• Schapira AH. (1999). Science, medicine, and the future: Parkinson’s disease. BMJ, 318:311–314.
   PubMed Web of Science ®Google Scholar
• Singh N, Pillay V, Choonara YE. (2007). Advances in the treatment of Parkinson’s disease. Prog Neurobiol, 81:29–44.
   PubMed Web of Science ®Google Scholar
• Moos T, Jensen PH. (2004). Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson’s disease autopsies. Acta Neuropathol, 107:23–26.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Shannak K, Hornykiewicz O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med, 318:876–880.
   PubMed Web of Science ®Google Scholar
• Wu SS, Frucht SJ. (2005). Treatment of Parkinson’s disease: what’s on the horizon? CNS Drugs, 19:723–743.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Koller WC. (1998). Advances in the treatment of Parkinson’s disease. Drugs Today, 34:95–105.
   PubMed Web of Science ®Google Scholar
• Zorc B, Ljubic M, Antolic S, Filipovic-Grcic J, Maysinger D et al. (1993). Macromolecular prodrugs. II. Esters of l-dopa and [alpha]-methyldopa. Int J Pharm, 99:135–143.
   Web of Science ®Google Scholar
• Whitney CM. (2007). Medications for Parkinson’s disease. Neurologist, 13:387–388.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53:283–318.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1–13.
   PubMed Web of Science ®Google Scholar
• Costantino L, Tosi G, Ruozi B, Bondioli L, Vandelli MA et al. (2009). Colloidal systems for CNS drug delivery. In: Hari Shanker S (ed.). Progress in Brain Research. Elsevier:Melbourne, Australia, 35–69.
   Google Scholar
• Anderson JM, Shive MS. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28:5–24.
   PubMed Web of Science ®Google Scholar
• Konstantinos A. (2004). Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv, 1:321–333.
   PubMedGoogle Scholar
• Fonseca C, Simões S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release, 83:273–286.
   PubMed Web of Science ®Google Scholar
• Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21:2475–2490.
   PubMed Web of Science ®Google Scholar
• Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release, 57:171–185.
   PubMed Web of Science ®Google Scholar
• Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E. (2004). Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res, 21:1428–1439.
   PubMed Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm, 336:367–375.
   PubMed Web of Science ®Google Scholar
• Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233:51–59.
   PubMed Web of Science ®Google Scholar
• Box GEP, Wilson KB. (1951). On the experimental attainment of optimum conditions. J R Stat Soc Ser B Stat Methodol, 13:1–45.
   Web of Science ®Google Scholar
• Myers RH, Montgomery DC. (2009). Response Surface Methodology: Process and Product Optimization using Designed Experiments. New York: Wiley.
   Google Scholar
• Box GEP, Hunter W, Hunter JS. (1978). Statistics for Experimenters: An Introduction to Design, Data Analysis and Model Building. New York: John Wiley and Sons.
   Google Scholar
• Cochran WG, Cox GM. (1957). Experimental Designs. New York: John Wiley and Sons.
   Google Scholar
• Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ et al. (1998). Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release, 50:31–40.
   PubMed Web of Science ®Google Scholar
• Illum L, Khan MA, Mak E, Davis SS. (1986). Evaluation of carrier capacity and release characteristics for poly( butyl 2-cyanoacrylate) nanoparticles. Int J Pharm, 30:17–28.
   Web of Science ®Google Scholar
• Song X, Zhao Y, Hou S, Xu F, Zhao R, He J et al. (2008). Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm, 69:445–453.
   PubMed Web of Science ®Google Scholar
• Feng SS, Mu L, Win KY, Huang G. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem, 11:413–424.
   PubMed Web of Science ®Google Scholar
• Freytag T, Dashevsky A, Tillman L, Hardee GE, Bodmeier R. (2000). Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J Control Release, 69:197–207.
   PubMed Web of Science ®Google Scholar
• Lewis GA, Mathieu D, Phan-Tan-Luu R. (1999). Pharmaceutical Experimental Design. New York: Markel Dekker.
   Google Scholar
• Montgomery DC. (1999). Design and Analysis of Experiments. New York: John Wiley and Sons.
   Google Scholar
• Higuchi T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52:1145–1149.
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123–133.
   PubMed Web of Science ®Google Scholar